多粘菌素
粘菌素
鲍曼不动杆菌
多粘菌素B
铜绿假单胞菌
微生物学
生物
抗药性
MCR-1型
肺炎克雷伯菌
基因
抗生素
肠杆菌科
细菌
遗传学
大肠杆菌
作者
Georgios Meletis,Lemonia Skoura
出处
期刊:Recent Patents on Anti-infective Drug Discovery
[Bentham Science]
日期:2018-11-26
卷期号:13 (3): 198-206
被引量:26
标识
DOI:10.2174/1574891x14666181126142704
摘要
The global spread of carbapenemase-encoding genes among Gram-negative nosocomial pathogens has led to the revival of polymyxins. Colistin and polymyxin B, despite their serious adverse effects, have become last resort treatment options for multi- or even extensively-drug-resistant bacterial infections due to Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa. Their use, however, has been followed by an increase in polymyxin resistance rates and the spread of transferable resistance genes limiting further the treatment options and contributing to the emergence of pan-drug-resistance. In the present review, the to-date known polymyxin resistance mechanisms, as well as patents related to polymyxin resistance, are discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI